Boris Peaker
Stock Analyst at TD Cowen
(2.14)
# 2,597
Out of 4,814 analysts
20
Total ratings
36.36%
Success rate
9.73%
Average return
Main Sectors:
Stocks Rated by Boris Peaker
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GLYC GlycoMimetics | Downgrades: Hold | n/a | $0.22 | - | 1 | Jul 26, 2024 | |
| MGNX MacroGenics | Downgrades: Hold | n/a | $1.38 | - | 3 | May 10, 2024 | |
| LNTH Lantheus Holdings | Initiates: Outperform | $100 | $100.62 | -0.62% | 1 | Dec 4, 2023 | |
| ADCT ADC Therapeutics | Downgrades: Market Perform | n/a | $1.22 | - | 1 | Nov 9, 2023 | |
| PCRX Pacira BioSciences | Upgrades: Outperform | $50 | $25.97 | +92.53% | 1 | Aug 3, 2023 | |
| PCVX Vaxcyte | Initiates: Outperform | n/a | $30.39 | - | 1 | Apr 18, 2023 | |
| XNCR Xencor | Initiates: Outperform | n/a | $10.58 | - | 1 | Dec 6, 2022 | |
| EBS Emergent BioSolutions | Maintains: Market Perform | $30 → $29 | $4.54 | +538.77% | 1 | Sep 12, 2022 | |
| CTMX CytomX Therapeutics | Downgrades: Market Perform | n/a | $0.74 | - | 2 | Jul 11, 2022 | |
| NKTR Nektar Therapeutics | Downgrades: Market Perform | n/a | $0.62 | - | 1 | Mar 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $10.44 | - | 1 | Jul 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $595.28 | - | 1 | Jun 12, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $95 → $102 | $77.85 | +31.02% | 1 | Jun 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.81 | - | 1 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.53 | - | 1 | Aug 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $0.55 | - | 1 | Oct 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $0.33 | - | 1 | Jul 24, 2017 |
GlycoMimetics
Jul 26, 2024
Downgrades: Hold
Price Target: n/a
Current: $0.22
Upside: -
MacroGenics
May 10, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.38
Upside: -
Lantheus Holdings
Dec 4, 2023
Initiates: Outperform
Price Target: $100
Current: $100.62
Upside: -0.62%
ADC Therapeutics
Nov 9, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $1.22
Upside: -
Pacira BioSciences
Aug 3, 2023
Upgrades: Outperform
Price Target: $50
Current: $25.97
Upside: +92.53%
Vaxcyte
Apr 18, 2023
Initiates: Outperform
Price Target: n/a
Current: $30.39
Upside: -
Xencor
Dec 6, 2022
Initiates: Outperform
Price Target: n/a
Current: $10.58
Upside: -
Emergent BioSolutions
Sep 12, 2022
Maintains: Market Perform
Price Target: $30 → $29
Current: $4.54
Upside: +538.77%
CytomX Therapeutics
Jul 11, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $0.74
Upside: -
Nektar Therapeutics
Mar 15, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $0.62
Upside: -
Jul 29, 2021
Initiates: Outperform
Price Target: n/a
Current: $10.44
Upside: -
Jun 12, 2017
Initiates: Outperform
Price Target: n/a
Current: $595.28
Upside: -
Jun 27, 2022
Maintains: Market Perform
Price Target: $95 → $102
Current: $77.85
Upside: +31.02%
Mar 3, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $0.81
Upside: -
Aug 13, 2021
Initiates: Outperform
Price Target: n/a
Current: $1.53
Upside: -
Oct 22, 2018
Initiates: Outperform
Price Target: n/a
Current: $0.55
Upside: -
Jul 24, 2017
Initiates: Outperform
Price Target: n/a
Current: $0.33
Upside: -